OKYO Pharma (NASDAQ:OKYO) Announces Earnings Results

OKYO Pharma (NASDAQ:OKYO) announced its quarterly earnings data on Monday. The company reported ($5.53) EPS for the quarter, missing the consensus estimate of ($0.08) by ($5.45), FiscalAI reports.

OKYO Pharma Stock Down 4.2%

NASDAQ:OKYO opened at $1.37 on Tuesday. OKYO Pharma has a 1 year low of $1.34 and a 1 year high of $3.35. The stock’s 50 day simple moving average is $1.59 and its two-hundred day simple moving average is $1.75.

Institutional Investors Weigh In On OKYO Pharma

Several large investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in OKYO Pharma during the third quarter valued at $31,000. XTX Topco Ltd bought a new stake in shares of OKYO Pharma in the 4th quarter worth about $36,000. Finally, Renaissance Technologies LLC increased its holdings in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares during the last quarter. Institutional investors own 2.97% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on OKYO. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a report on Friday. HC Wainwright lowered their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, OKYO Pharma currently has an average rating of “Hold” and an average target price of $5.67.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.